You are here

Summary of Remarks from FDA's Meeting on Biosimilars

Stakeholders Nov. 2 provided input to the Food and Drug Administration for its creation of an abbreviated pathway for biosimilars or follow-on biologics, with pharmacies expressing concern that new patient barriers will be imposed for these drugs, patient and physician groups advocating clinical trials and no automatic pharmacy substitution, and biopharmaceutical companies urging caution.

News Category: